Didymin by suppressing NF-κB activation prevents VEGF-induced angiogenesis in vitro and in vivo.


Journal

Vascular pharmacology
ISSN: 1879-3649
Titre abrégé: Vascul Pharmacol
Pays: United States
ID NLM: 101130615

Informations de publication

Date de publication:
04 2019
Historique:
received: 08 05 2018
revised: 05 11 2018
accepted: 07 01 2019
pubmed: 12 1 2019
medline: 1 8 2019
entrez: 12 1 2019
Statut: ppublish

Résumé

Although didymin, a dietary flavonoid glycoside from citrus fruits, known to be a potent antioxidant with anti-cancer activities, its role in angiogenesis is not known. In this study, we examined the effect of didymin on VEGF-induced angiogenesis in vitro and in vivo models. Our results suggest that treatment of human umbilical vein endothelial cell (HUVECs) with didymin significantly prevented the VEGF-induced cell proliferation, migration, and invasion. Further, didymin significantly prevented the VEGF-induced endothelial tube formation in culture. Didymin also attenuated the VEGF-induced generation of ROS, activation of NF-κB and the expression of adhesion molecules such as VCAM-1, ICAM-1, and E-selectin in HUVECs. Further, didymin also prevented the VEGF-induced microvessel sprouting in ex vivo mouse aortic rings. Most importantly, didymin significantly prevented the invasion of endothelial cells and formation of blood capillary-like structures in Matrigel plug model of angiogenesis in mice. Thus, our results suggest a novel antiangiogenic efficacy of didymin in addition to its reported anti-cancer properties, which warrant further development of this agent for cancer therapy.

Identifiants

pubmed: 30634049
pii: S1537-1891(18)30168-X
doi: 10.1016/j.vph.2019.01.002
pii:
doi:

Substances chimiques

Angiogenesis Inducing Agents 0
Angiogenesis Inhibitors 0
Cell Adhesion Molecules 0
Flavonoids 0
Glycosides 0
NF-kappa B 0
Reactive Oxygen Species 0
Vascular Endothelial Growth Factor A 0
didymin 0

Types de publication

Journal Article

Langues

eng

Pagination

18-25

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Kirtikar Shukla (K)

Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston TX-77555, USA.

Himangshu Sonowal (H)

Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston TX-77555, USA.

Ashish Saxena (A)

Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston TX-77555, USA.

Kota V Ramana (KV)

Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston TX-77555, USA. Electronic address: kvramana@utmb.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH